SMAD4 and pancreatic neoplasm: SMAD4 is also mutated or deleted in 10%–15% and 20%–50% of colorectal and pancreatic cancers, respectively (10–12), in which its loss of expression is associated with inferior outcomes in patients with colorectal cancer (13–15) and pancreatic cancer (16–18).